Medical Oncology Divisions
Division of Hematologic Malignancies
The Division of Hematologic Malignancies consists of specialized physicians with expertise in various hematologic cancers and palliative care. This team offers advanced clinical care and research opportunities focused on leukemias, myelodysplastic syndromes (MDS), lymphomas, and multiple myeloma-related conditions.
Division of Transplant & Cell Therapies
Founded in 1995, the Division of Transplant & Cell Therapies (TCT) at Thomas Jefferson University Hospital has been a leader in advancing treatment for hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. The program offers both autologous and allogeneic stem cell transplants and holds full accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT), a recognition of its commitment to the highest national standards in transplant and cellular therapy care.
Division of Population Science
In 2008, the Department of Medical Oncology and the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University established the Division of Population Science to provide a central focus for institutional research activities related to cancer prevention and control.
Division of Solid Tumor Oncology
The Division of Solid Tumor is composed of a group of dedicated physicians that have developed disease-oriented subspecialty programs in solid tumor cancers. These physicians work closely with their surgical and radiation oncology colleagues in a multi-disciplinary setting to deliver integrative care with cutting edge research.
Division of Supportive Oncology
The Division of Supportive Oncology at Sidney Kimmel Comprehensive Cancer Center (SKCCC), part of Jefferson Health, is a nationally recognized, integrated model of care that focuses on improving quality of life for patients and families affected by cancer. The division is deeply committed to treating the whole person; addressing not only the physical aspects of cancer but also the emotional, spiritual, and practical challenges that accompany it.